TGFB1 is a pivitol regulator of endometriotic lesion development
TGFB1 is a pivitol regulator of endometriotic lesion development
批准号:
nhmrc : 1012950
负责人:
A/Pr Mary (Louise) Hull
金额:
$29.26万
依托单位国家:
澳大利亚
项目类别:
NHMRC Project Grants
财政年份:
2011
资助国家:
澳大利亚
项目状态:
已结题
起止时间:
2011-01-01 至 2013-12-31
中文摘要
子宫内膜异位症发生时,内衬子宫的组织被发现在盆腔。10%的育龄妇女患有子宫内膜异位症,并患有虚弱的盆腔疼痛和生育能力低下。我们已经证明,转化生长因子(TGFB1)是子宫内膜异位症生长的核心,它的缺乏抑制疾病的发展。我们希望阐明TGFB1在子宫内膜异位症中的作用,以便为患有这种疾病的女性提供更好的治疗选择。
英文摘要
Endometriosis occurs when the tissue that lines the womb is found in the pelvic cavity. 10% of reproductive aged women have endometriosis and suffer from debilitating pelvic pain and subfertility. We have shown that transforming growth factor (TGFB1) is central to the growth of endometriosis and that its absence suppresses disease development. We hope to clarify the role of TGFB1 in endometriosis, in order to develop better therapeutic options for women incapacitated by this disease.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文